Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 18

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 18
---
 If we do not meet our obligations under our in-license agreements in a timely manner, we could lose the rights
to our proprietary technology, which could have a material adverse effect on our business, financial condition and results of operations.

We have partnered with and
may seek to partner with third-party collaborators with respect to the development and commercialization of motixafortide and for any
other therapeutic candidate and we may not succeed in establishing and maintaining collaborative relationships, which may significantly
limit our ability to develop and commercialize our therapeutic candidates successfully, if at all.

We collaborate with third parties with respect to the development
of motixafortide for certain indications and may in the future seek a partner for other indications or other therapeutic candidates. In
October 2023, we out-licensed the rights to motixafortide for all indications in substantially all of Asia to Gloria, and in November
2024, we out-licensed the global rights (other than in Asia) to motixafortide for all indications, other than solid tumors, to Ayrmid.
See “ Item 4. B. Information on the Company - Business Overview - Recent Developments”. We may compete with many other
companies if we seek additional partners for motixafortide and for any other therapeutic candidate and we may not be able to compete successfully
against those companies. If we are not able to enter into additional collaboration arrangements for motixafortide and for any other therapeutic
candidate, we would be required to undertake and fund further development, clinical trials, manufacturing and commercialization activities
solely at our own expense and risk, as is the case with motixafortide in stem cell mobilization for autologous bone marrow transplantation
in multiple myeloma patients in the U. S. If we are unable to finance and/or successfully execute those expensive activities, or we delay
such activities due to capital availability, our business could be materially and adversely affected, and potential future product launch
could be materially delayed, be less successful, or we may be forced to discontinue clinical development of these therapeutic candidates.
Furthermore, if we are unable to enter into a commercial agreement for the development and commercialization of motixafortide and for
any other therapeutic candidate, then this could have a material adverse effect on our business, financial condition or results of operations.

The process of establishing and maintaining collaborative relationships
is difficult, time-consuming and involves significant uncertainty, including:

  a collaboration partner may shift its priorities                                                                                          
  and resources away from our